Rahul Aggarwal, MD, on Clinical Implications of the PRESTO Study Findings in Prostate Cancer

Posted: Friday, March 31, 2023

Rahul Aggarwal, MD, of the University of California, San Francisco, discusses practical clinical considerations of recent phase III findings, which showed that apalutamide plus androgen-deprivation therapy (ADT) for 12 months significantly prolonged PSA progression-free survival compared with ADT alone in patients with biochemically recurrent prostate cancer.

---